Epizyme Receivables

Epizyme (EPZM) currently reports a receivables of $11M as of June 2022. That compares with $7.1M in the prior-year period — up 57.5% year over year. Use the charts on this page to explore Epizyme's receivables history and peer comparisons.

Epizyme's receivables increased from $7.1M to $11M — a 57.5% year-over-year increase (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Epizyme reported $11M in receivables as of June 2022. That compares with $7.1M in the prior-year period — up 57.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Epizyme, and consider following EPZM for alerts when major investors trade the stock.

Epizyme is classified in the Healthcare sector. On receivables, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EPZM with unrelated industries.